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The dramatic increase in obesity and diabetes worldwide
poses a huge socioeconomic burden to healthcare systems.
In type 1 diabetes, autoimmune-mediated destruction of pan-
creatic beta-cell results in insulin deficiency [1]. Obesity is
one of the major causes of type 2 diabetes [1–3]. In type
2 diabetes, a combination of peripheral insulin resistance
and aberrant production of insulin are amongst the paradox
commonly encountered in the pathogenesis of the disease [1–
3]. However, both forms of diabetes are characterized by ele-
vated inflammation/oxidative stress, glucotoxicity, lipotox-
icity, endoplasmic reticulum-induced stress with increased
apoptosis and necrosis that ultimately leads to destruc-
tion loss of beta cells, and related complications including
cardiomyopathy, nephropathy, neuropathy, and hepatopathy
[1, 4–7]. Although insulin resistance has traditionally been
associated with type 2 diabetes, recent evidence suggests
that insulin resistance in type 1 diabetes is increasing [8–10];
therefore, novel mechanistic approaches deciphering insulin
resistance are needed.
The etiology of insulin resistance is complicated and sev-
eral factors are implicated, so deciphering this multifaceted
disease remains challenging, although a wide body of evi-
dence suggests that oxidative stress, inflammation, genetic,
habitual, environmental, and epigenetic factors may be in-
volved [1, 11]. Thus, further research is needed for more in-
depth and comprehensive understanding of the pathophysi-
ology of insulin resistance in both type 1 and type 2 diabetes,
and especially in situations where diabetes is comorbid with
other chronic conditions such as obesity and hypertension.
This special issue will showcase a broad spectrum
research and review papers addressing thematic problems
associated with insulin resistance, type 1 diabetes, type 2
diabetes, and related complications. To underscore the role of
insulin resistance in children, M. P. van der Aa et al. wrote a
research article on the prevalence and incidence of childhood
insulin resistance, while S.-H. Nam and coworkers investi-
gated the effects of cardioankle vascular index on metabolic
syndrome, amultifactorial condition characterized by insulin
resistance, dyslipidemia, hyperglycemia, hypertension, and
other factors. Similarly, R. Burrows et al. gave further insights
for diagnosing metabolic syndrome in adolescents in a
research article. In another related research article, M. Fabre-
gat et al. investigated the genetic profile of human leukocyte
antigen (HLA) alleles and non-HLA in type 2 diabetes,
while P. Tiwari wrote a systematic review about the current
therapeutic strategies for the management of diabetes. Given
that diabetes and hypertension are characterized by elevated
inflammation/oxidative stress [4, 12–14] and these two patho-
physiological driving forces are implicated in many cardiac
complications [4, 12–14], J. Klen et al. investigated the role
of NLRP3 inflammasome polymorphism in type 2 diabetes,
shedding novel insights on the role of NLRP3 polymorphism
on myocardial infarction, a macrovascular complication of
diabetes. Similarly, H. Al-Safar et al. investigated the role
of genetic polymorphisms on transcription-factor-7-like 2
and peroxisome proliferator-activated receptors-𝛾2 in type 2
diabetes and obesity, while M. Guclu et al. wrote a research
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article about the effects of combination therapy with rosigli-
tazone and insulin on inflammatory insults in patients with
type 1 diabetes. In another related research article, Z. Yida
et al. reported that cotreatment with the cholesterol lowering
drug simvastatin and edible bird’s nest (EBN), a traditional
product commonly consumed in Asia for its nutritional
value, improved insulin signaling in a rat model of high-
fat diet-induced insulin resistance. Consistently, in another
related study, A. Ferreira-Hermosillo et al. gave further
insights on the role of inflammatory cytokines in patients
with metabolic syndrome. Within the same theme of insulin
resistance andmetabolic syndrome, R. Adela and S. K. Baner-
jee wrote a review article to underscore the role of growth-
differentiation-factor-15 in diabetes and related cardiovascu-
lar diseases, whereas J. Zhang et al. gave further insights on
obesity and type 2 diabetes in a research article. By the same
token, T.-Y. Chuang et al. reported the effects of microRNA-
223 on insulin resistance by studying the adipose tissue.
Finally, S. Riaz wrote an article giving novel insights on the
role of Vitamin B1 on biomarkers of diabetes type 2 diabetes.
Collectively, the articles featured in this special issue cover
awide spectrumof thematic issues of great interest andwould
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